The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Open accessAbstract
BACKGROUND: Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects of four immunosuppressive regimens. METHODS: We randomly assigned 1645 renal-transplant recipients to receive standard-dose cyclosporine, mycophenolate mofetil, and corticosteroids, or daclizumab induction, mycophenolate mofetil, and corticosteroids in combination with low-dose cyclosporine, low-dose tacrolimus, or low-dose sirolimus. The primary end point was the estimated glomerular filtration rate (GFR), as calculated by the Cockcroft-Gault formula, 12 months after transplantation. Secondary end points included acute rejection and allograft survival. RESULTS: The mean calculated GFR was higher in patients receiving low-dose tacrolimus (65.4 ml per minute) than in the other three groups (range, 56.7 to 59.4 ml per minute). The rate of biopsy-proven acute rejection was lower in patients receiving low-dose tacrolimus (12.3%) than in those receiving standard-dose cyclosporine (25.8%), low-dose cyclosporine (24.0%), or low-dose sirolimus (37.2%). Allograft survival differed significantly among the four groups (P=0.02) and was highest in the low-dose tacrolimus group (94.2%), followed by the low-dose cyclosporine group (93.1%), the standard-dose cyclosporine group (89.3%), and the low-dose sirolimus group (89.3%). Serious adverse events were more common in the low-dose sirolimus group than in the other groups (53.2% vs. a range of 43.4 to 44.3%), although a similar proportion of patients in each group had at least one adverse event during treatment (86.3 to 90.5%). CONCLUSIONS: A regimen of daclizumab, mycophenolate mofetil, and corticosteroids in combination with low-dose tacrolimus may be advantageous for renal function, allograft survival, and acute rejection rates, as compared with regimens containing daclizumab induction plus either low-dose cyclosporine or low-dose sirolimus or with standard-dose cyclosporine without induction. (ClinicalTrials.gov number, NCT00231764 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Groth, C. G., Bäckman, L., Morales, J.-M., Calne, R., Kreis, H., Lang, P., Touraine, J.-L., Claesson, K., Campistol, J. M., Durand, D., et al. (1999) · Transplantation · doi:10.1097/00007890-199904150-00017 · Cited by 878
Strategies to Improve Long-Term Outcomes after Renal Transplantation
Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N., & Cosimi, A. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011295 · Cited by 844
Webster, A. C., Woodroffe, R. C., Taylor, R. S., Chapman, J. R., & Craig, J. C. (2005) · BMJ · doi:10.1136/bmj.38569.471007.ae · Cited by 587
Kreis, H., Cisterne, J.-M., Land, W., Wramner, L., Squifflet, J.-P., Abramowicz, D., Campistol, J. M., Morales, J.-M., Grinyo, J.-M., Mourad, G., et al. (2000) · Transplantation · doi:10.1097/00007890-200004150-00009 · Cited by 536
Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Chapman, J. R., & Allen, R. D. M. (2004) · Transplantation · doi:10.1097/01.tp.0000128636.70499.6e · Cited by 498
Margreiter, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07875-3 · Cited by 450
Self-citationDean, P. G., Lund, W. J., Larson, T. S., Prieto, M., Nyberg, S. L., Ishitani, M. B., Kremers, W. K., & Stegall, M. D. (2004) · Transplantation · doi:10.1097/01.tp.0000123082.31092.53 · Cited by 332
HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION
Kobashigawa, J. A., & Kasiske, B. L. (1997) · Transplantation · doi:10.1097/00007890-199702150-00001 · Cited by 314
Flechner, S. M., Kurian, S. M., Solez, K., Cook, D. J., Burke, J. T., Rollin, H., Hammond, J. A., Whisenant, T., Lanigan, C. M., Head, S. R., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00627.x · Cited by 281
Burdmann, E. A., Andoh, T. F., Yu, L., & Bennett, W. M. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00090-1 · Cited by 258
Rostaing, L., Cantarovich, D., Mourad, G., Budde, K., Rigotti, P., Mariat, C., Margreiter, R., Capdevilla, L., Lang, P., Vialtel, P., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000154915.20524.0a · Cited by 249
Self-citationLanger, R. M., & Kahan, B. D. (2002) · Transplantation · doi:10.1097/00007890-200209270-00012 · Cited by 162
Mechanism of Cyclosporine-Induced Hypertension
Luke, R. G. (1991) · American Journal of Hypertension · doi:10.1093/ajh/4.5.468 · Cited by 100
Hypertension Following Kidney Transplantation
Curtis, J. J. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)81015-8 · Cited by 73
Hypertensinogenic mechanism of the calcineurin inhibitors
Curtis, J. J. (2002) · Current Hypertension Reports · doi:10.1007/s11906-002-0067-5 · Cited by 55
Sperschneider, H. (2001) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)02477-5 · Cited by 40
Cited by
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Linkermann, A., & Green, D. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1310050 · Cited by 1,103
Haas, M., Loupy, A., Lefaucheur, C., Roufosse, C., Glotz, D., Seron, D., Nankivell, B. J., Halloran, P. F., Colvin, R. B., Akalin, E., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14625 · Cited by 1,041
Self-citationVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Self-citation
Metadata
- Authors
- Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., Vanrenterghem, Y., Daloze, P., & Halloran, P. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-12-20
- Volume
- 357
- Issue
- 25
- Pages
- 2562-2575
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142288396
- Cited by
- 1,810
- References
- 17
- FWCI
- 53.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.